Skip to main
ABVX

Abivax SA (ABVX) Stock Forecast & Price Target

Abivax SA (ABVX) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 33%
Buy 58%
Hold 8%
Sell 0%
Strong Sell 0%

Bulls say

Abivax is a biotechnology company focused on developing innovative therapies for chronic inflammatory diseases, particularly in the area of inflammatory bowel diseases such as ulcerative colitis and Crohn's disease. The recent successful Part 2 maintenance readout for its lead drug candidate, obefazimod, reinforces its best-in-class efficacy and further removes previous concerns about malignancy risks. Despite a recent stock price increase, the company's significant financial runway and upcoming catalysts, including the presentation of full Part 1 UC maintenance data and potential partnership opportunities, provide significant upside potential for investors.

Bears say

Abivax is focused solely on the research and development of obefazimod, an oral therapy for inflammatory bowel diseases, with a projected topline for its Phase 3 trial in ulcerative colitis pushed to mid-2027 due to competitive enrollment processes. However, the extended runway provides an opportunity for the company to broaden the study, potentially enhancing its quality and positioning obefazimod as an early treatment option for IBD. And, lack of correlation between non-melanoma skin cancers (NMSCs) and skin lesions provides further reassurance about the safety of the drug in this regard.

Abivax SA (ABVX) has been analyzed by 12 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 58% recommend Buy, 8% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Abivax SA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Abivax SA (ABVX) Forecast

Analysts have given Abivax SA (ABVX) a Buy based on their latest research and market trends.

According to 12 analysts, Abivax SA (ABVX) has a Buy consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $152.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $152.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Abivax SA (ABVX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.